Physician profile
Alan Deangelo
NPI 1982741237
$10,525.85
in general payments reported to CMS, 2019-2025
32 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $929 · 2021: $4,063 · 2022: $1,452 · 2023: $1,151 · 2024: $1,381 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,964 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,963.53 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,881.60 | 2020-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,599.66 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,550.23 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Ethicon INC. | $533.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.03 | 2021-2025 | Ofev |
| Genzyme Corporation | $241.67 | 2023-2025 | |
| Amgen INC. | $193.95 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $186.26 | 2023-2024 | Keytruda, Winrevair |
| Fisher & Paykel Healthcare INC | $185.30 | 2025 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $174.33 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $169.98 | 2020-2025 | |
| Inspire Medical Systems, INC. | $163.17 | 2022-2023 | Inspire |
| Harmony Biosciences LLC | $160.41 | 2021-2025 | Wakix |
| Ani Pharmaceuticals, INC. | $143.46 | 2023-2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $125.60 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $121.07 | 2022-2023 | Prolastin-C Liquid |
| Noah Medical Corporation | $108.94 | 2024 | Galaxy |
| Actelion Pharmaceuticals US, INC. | $95.46 | 2021-2023 | Opsumit |
| Verona Pharma, INC. | $85.39 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $82.35 | 2022-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $77.33 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $68.80 | 2022-2024 | Yupelri |
| Lilly USA, LLC | $63.13 | 2025 | Zepbound |
| Philips North America LLC | $39.03 | 2022-2025 | Vest Therapy Und |
| Electromed, INC. | $36.19 | 2021-2023 | Smartvest |
| Stryker Corporation | $22.12 | 2025 | Flowtriever |
| Inari Medical, INC. | $17.39 | 2021 | |
| Covidien LP | $17.17 | 2020 | |
| Abbvie INC. | $17.10 | 2021 | |
| Melinta Therapeutics, LLC | $14.96 | 2022 | |
| Insmed, INC. | $13.46 | 2021 | |
| Advanced Respiratory, INC | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Deangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.